Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
Camp4 Therapeutics Corp (CAMP) is the subject of an Amendment No. 3 to Schedule 13D filed by several 5AM venture funds and managing members Andrew J. Schwab and Dr. Kush Parmar, updating their beneficial ownership and recent trading activity in Camp4 common stock.
The reporting group’s beneficial ownership is based on 62,753,200 shares outstanding as of August 12, 2026. Schwab is deemed to beneficially own 6,379,125 shares (including 9,000 vested options), representing 9.99% of the common stock, and Parmar is deemed to beneficially own 6,370,125 shares, or 9.98%. Ventures VI holds 2,033,270 shares, Ventures VII holds 2,941,176 shares plus Pre-Funded Warrants for up to 3,179,558 shares, and Opportunities II holds 302,770 shares.
The filing details recent sales by Ventures VI between August 19 and 27, 2026, including open market sales totaling over 190,000 shares at weighted average prices around $4.50–$4.76 and a block sale of 400,000 shares at $4.04. A Beneficial Ownership Blocker in the Pre-Funded Warrants limits Ventures VII’s exercise so that, after exercise, affiliated holders do not exceed 9.99% of Camp4’s outstanding common stock.
Camp4 Therapeutics Corp (CAMP) director Andrew J. Schwab, through an affiliated investment fund, reported selling 400,000 shares of common stock on 2026-08-27 at $4.04 per share. After this sale, 5AM Ventures VI, L.P. held 2,033,270 shares, and affiliated funds 5AM Ventures VII, L.P. and 5AM Opportunities II, L.P. held 2,941,176 and 302,770 shares, respectively. The filing states these positions are held indirectly through 5AM entities and that Schwab disclaims beneficial ownership beyond his pecuniary interest.
Camp4 Therapeutics Corp (CAMP) director Andrew J. Schwab reported a small sale of 10 shares of common stock on 2026-08-24 at $4.50 per share. The shares are held indirectly through 5AM Ventures VI, L.P., with Schwab reporting shared voting and investment power through his role at its general partner and disclaiming beneficial ownership except for his pecuniary interest.
Following this transaction, entities associated with Schwab reported indirect holdings of 2,433,270 shares via 5AM Ventures VI, L.P., 2,941,176 shares via 5AM Ventures VII, L.P., and 302,770 shares via 5AM Opportunities II, L.P. The filing does not indicate use of a Rule 10b5-1 trading plan.
Camp4 Therapeutics Corp (CAMP) reports that director Andrew J. Schwab, through affiliated fund 5AM Ventures VI, L.P., sold 191,865 shares of Common Stock over August 19–21, 2026 in open-market or private transactions. The sales were indirect, by 5AM Ventures VI, with Schwab disclaiming beneficial ownership beyond his pecuniary interest.
The sales comprised 45,147 shares on August 19 at a weighted average $4.76 (individual trades from $4.75–$5.00), 114,700 shares on August 20 at a weighted average $4.54 (from $4.50–$4.91), and 32,018 shares on August 21 at a weighted average $4.50 (from $4.50–$4.53). Separate holding entries show 2,941,176 shares held by 5AM Ventures VII, L.P. and 302,770 shares held by 5AM Opportunities II, L.P., both reported as indirect interests with similar beneficial-ownership disclaimers.
Camp4 Therapeutics Corp (CAMP) reported an insider sale by Chief Scientific Officer Daniel Tardiff. On August 19, 2026, he sold 1,738 shares of common stock in a sale characterized as an open market or private transaction at $4.76 per share. Following this transaction, his reported direct holdings of common stock from this lot were 0 shares. The shares had been previously acquired through the company’s Employee Stock Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026 in a transaction described as exempt under Rule 16b-3(c).
Camp4 Therapeutics Corporation (CAMP) received an amended Schedule 13D/A from Polaris-affiliated funds and individuals updating their ownership in the company’s common stock. The amendment states it is being filed to reflect a lower ownership percentage resulting from dilution caused by Camp4’s sales of additional common shares since the prior amendment.
Polaris Management Co. VII, L.L.C., as general partner of Polaris Partners VII, L.P. and Polaris Entrepreneurs’ Fund VII, L.P., reports beneficial ownership of 3,023,161 shares, or 4.8% of Camp4’s common stock, all with shared voting and dispositive power. Polaris Partners VII, L.P. holds 2,825,500 shares (about 4.5%), and Polaris Entrepreneurs’ Fund VII, L.P. holds 197,661 shares (about 0.3%). Polaris Partners X, L.P. reports 909,090 shares (about 1.4%), with control through Polaris Partners GP X, L.L.C.
Individually, board member Amir Nashat is deemed to beneficially own an aggregate of 3,932,251 shares, representing approximately 6.3% of Camp4’s outstanding common stock, through interests in these Polaris entities. All reported ownership percentages are based on 62,753,200 common shares outstanding as of August 12, 2026, as reported by Camp4 in its Form 10-Q.
Camp4 Therapeutics Corp (CAMP) received a notice that affiliate Daniel Tardiff, through J.P. Morgan Securities LLC as agent, plans to sell 1,738 shares of common stock under Rule 144. The proposed sale is valued at approximately $8,275.55 with an anticipated sale date of August 19, 2026. The filing also notes an earlier 434-share ESPP issuance on July 2, 2026 for cash.
Balyasny Asset Management and related entities reported beneficial ownership of Camp4 Therapeutics Corp. common stock. Through Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., the reporting group may be deemed to beneficially own 2,591,097 shares of common stock. This represents approximately 4.99% of the outstanding shares, based on 51,925,800 shares outstanding as of May 6, 2026. The position includes common shares and shares issuable upon exercise of warrants that are subject to a 4.99% Beneficial Ownership Limitation, which blocks warrant exercises that would push ownership above that level. The reporting persons have sole voting and dispositive power over the reported shares and disclose that the underlying funds, ADMF and APHC, are entitled to dividends and sale proceeds.
CAMP4 Therapeutics Corporation reported for the quarter ended June 30, 2026 that it remains a clinical-stage company focused on RNA-targeting therapeutics, with lead candidate CMP-002 for SYNGAP1-related disorder. Research and collaboration revenue was $1.8 million for the quarter and $3.1 million year-to-date, largely from its collaboration with GSK.
Operating expenses stayed high as development advanced, with R&D of $20.98 million and G&A of $8.55 million for the six-month period. A large non-cash $27.12 million loss from remeasurement of a derivative tranche liability tied to a private placement drove the six‑month net loss to $51.86 million and turned stockholders’ equity into a small deficit.
Cash and cash equivalents were $86.40 million at June 30, 2026, with total cash, cash equivalents and restricted cash of $88.02 million and negative operating cash flow of $23.67 million for the first half. Management states that existing cash plus $46.9 million of proceeds received in August 2026 from the second closing of the private placement are expected to fund operations through the end of 2028. Subsequent to quarter-end, regulatory clearances in Australia and Argentina allow initiation of a Phase 1/2 trial of CMP‑002.
CAMP4 Therapeutics reported second quarter 2026 results and clinical progress. Research and collaboration revenue was $1.8 million for the quarter, compared with $1.5 million a year earlier. Research and development expenses were $10.8 million, and general and administrative expenses were $4.3 million, both slightly higher than the prior year period.
Net loss increased to $33.5 million from $12.6 million, driven largely by a $20.9 million non-cash loss from the change in fair value of a derivative tranche liability related to a 2025 private placement. Cash and cash equivalents were $86.4 million as of June 30, 2026, with an additional $50.1 million raised after quarter-end, and the company states this cash is expected to fund planned activities through the end of 2028.
Operationally, CAMP4 obtained regulatory clearance in Australia and Argentina to initiate a first-in-human Phase 1/2 trial of CMP-002 in SYNGAP-1 related disorder, submitted regulatory filings in the EU and UK, completed a second closing of its private placement, and relocated its headquarters to Watertown, Massachusetts.